Gene therapy
News
November 19, 2024
Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago
(read more)
October 21, 2024
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy
(read more)
September 17, 2024
Genethon and Samabriva strengthen their partnership to develop of a cost-effective plant-based AAV manufacturing process for greater patient access to gene therapies.
(read more)
September 12, 2024
Genethon Announces Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety
(read more)
September 6, 2024
Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patientsfor 35 years and Provides an Update on Its PromisingGene Therapy Drug Candidate for This Fatal Disease
(read more)
May 3, 2024
Genethon’s Scientists Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 7-11, 2024, in Baltimore, MD
(read more)
April 23, 2024
First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy presented at International Myology 2024 Congress
(read more)
April 22, 2024
Genethon will introduce its latest advances in gene therapy research in multiple presentations at the International Myology 2024 Congress
(read more)
March 4, 2024
Clinical results of the gene therapy trial in myotubular myopathy: efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead
(read more)
February 28, 2024
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases
(read more)
February 7, 2024
The American organization Team Titin awards its first research grant funding to Genethon
(read more)
November 30, 2023
Genethon evaluates a new therapeutic approach for glycogen storage disease III
(read more)
November 21, 2023
NEWSLETTER : “We have multiple examples of how these technologies can be used to develop products that more efficient and safer with improved production technologies”
(read more)
November 17, 2023
Myotubular myopathy: gene therapy trial results demonstrate major improvement of motor and respiratory functions
(read more)
November 17, 2023
Clinical results of the gene therapy trial in myotubular myopathy : efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead
(read more)
October 27, 2023
First clinical results of a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy presented at ESGCT Congress
(read more)
October 24, 2023
The Latest Research of 14 Généthon Scientists to be Featured at the European Society of Gene & Cell Therapy’s 30th Annual Congress, Oct. 24-27, 2023, in Brussels, Belgium
(read more)
September 15, 2023
Genethon assesses a therapeutic potential of a Dual AAV vector approach for Duchenne muscular dystrophy
(read more)
September 11, 2023
Genethon’s Optidys project rewarded by BpiFrance as part of France 2030
(read more)
Serving the public interest
Our mission: Conception, clinic and preclinic development of drugs of genic therapy for rare diseases
Our goal: Providing these innovative treatments to the sick
Our science
Act for the general interest
Our mission: the design and preclinical and clinical development of gene therapy drugs for rare diseases.
Our objective: to make these innovative treatments available to patients.
